NASDAQ:HCM HUTCHMED (HCM) Stock Price, News & Analysis $16.31 -1.61 (-8.98%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$15.15 -1.16 (-7.11%) As of 09:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HUTCHMED Stock (NASDAQ:HCM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HUTCHMED alerts:Sign Up Key Stats Today's Range$15.57▼$17.2350-Day Range$13.60▼$19.2152-Week Range$11.51▼$21.50Volume116,089 shsAverage Volume34,068 shsMarket Capitalization$2.84 billionP/E RatioN/ADividend YieldN/APrice Target$28.00Consensus RatingModerate Buy Company Overview HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong. Read More HUTCHMED Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreHCM MarketRank™: HUTCHMED scored higher than 53% of companies evaluated by MarketBeat, and ranked 337th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingHUTCHMED has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHUTCHMED has only been the subject of 2 research reports in the past 90 days.Read more about HUTCHMED's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth812.50% Earnings GrowthEarnings for HUTCHMED are expected to grow by 812.50% in the coming year, from $0.16 to $1.46 per share.Price to Book Value per Share RatioHUTCHMED has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.20% of the outstanding shares of HUTCHMED have been sold short.Short Interest Ratio / Days to CoverHUTCHMED has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in HUTCHMED has recently decreased by 15.43%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHUTCHMED does not currently pay a dividend.Dividend GrowthHUTCHMED does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.20% of the outstanding shares of HUTCHMED have been sold short.Short Interest Ratio / Days to CoverHUTCHMED has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in HUTCHMED has recently decreased by 15.43%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for HUTCHMED this week, compared to 3 articles on an average week.Search Interest2 people have searched for HCM on MarketBeat in the last 30 days. MarketBeat Follows1 people have added HUTCHMED to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, HUTCHMED insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of HUTCHMED is held by insiders.Percentage Held by InstitutionsOnly 8.82% of the stock of HUTCHMED is held by institutions.Read more about HUTCHMED's insider trading history. Receive HCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter. Email Address HCM Stock News HeadlinesHUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call Transcript5 hours ago | seekingalpha.comHUTCHMED to Announce 2025 Half-Year Financial ResultsJuly 3, 2025 | globenewswire.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 8 at 2:00 AM | Brownstone Research (Ad)HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor TherapyJune 30, 2025 | globenewswire.comHUTCHMED (China) Limited (HCM.L) - Yahoo FinanceJune 26, 2025 | nz.finance.yahoo.comHUTCHMED (China) Limited (HCM) - Yahoo FinanceJune 26, 2025 | au.finance.yahoo.comHow Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52% - NasdaqJune 25, 2025 | nasdaq.comPaycom Software: Automating Payroll And HCM Solutions; Initiate With 'Buy'June 22, 2025 | seekingalpha.comSee More Headlines HCM Stock Analysis - Frequently Asked Questions How have HCM shares performed this year? HUTCHMED's stock was trading at $14.41 at the start of the year. Since then, HCM shares have increased by 13.2% and is now trading at $16.31. When did HUTCHMED IPO? HUTCHMED (HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers. Who are HUTCHMED's major shareholders? Top institutional shareholders of HUTCHMED include Allianz Asset Management GmbH (0.53%), M&G PLC (0.15%), Vanguard Personalized Indexing Management LLC (0.01%) and Janney Capital Management LLC (0.01%). How do I buy shares of HUTCHMED? Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HUTCHMED own? Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Today8/07/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HCM CIK1648257 Webwww.chi-med.com Phone852-2121-3888Fax852-2128-1778Employees1,811Year Founded2000Price Target and Rating Average Price Target for HUTCHMED$28.00 High Price Target$28.00 Low Price Target$28.00 Potential Upside/Downside+71.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.08 Current Ratio2.83 Quick Ratio2.70 Sales & Book Value Annual Sales$630.20 million Price / Sales4.51 Cash Flow$0.26 per share Price / Cash Flow62.41 Book Value$4.43 per share Price / Book3.68Miscellaneous Outstanding Shares174,420,000Free Float168,143,000Market Cap$2.84 billion OptionableNot Optionable Beta0.55 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:HCM) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.